Neural Stem Cell Transplantation in Multiple Sclerosis Patients
Status:
Completed
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
This is a phase I study evaluating the feasibility, safety and tolerability of intrathecally
administered human Neural Stem Cells (hNSCs), at an escalating dose ranging from 0.7x10^6±10%
cells to 5.7x10^6±10% cells/kg of body weight, in patients affected by Progressive Multiple
Sclerosis